BI
Therapeutic Areas
Xencor Pipeline
| Drug | Indication | Phase |
|---|---|---|
| XmAb 14045 | Cancer | Clinical |
| XmAb 13676 | Cancer | Clinical |
| Ultomiris (ravulizumab-cwvz) | PNH, aHUS, gMG, NMOSD | Approved/Commercial |
| Monjuvi (tafasitamab-cxix) | Relapsed/Refractory Follicular Lymphoma; r/r DLBCL | Approved/Commercial |
| Vibostolimab | Cancer | Clinical |
| Plonmarlimab | Autoimmune Disease | Clinical |
Leadership Team at Xencor
JR
John R. Desjarlais, Ph.D.
Executive Vice President, Research & Chief Scientific Officer
DL
Dane Leone
Executive Vice President & Chief Strategy Officer
BC
Bart Cornelissen
Senior Vice President & Chief Financial Officer
CE
Celia Eckert, J.D.
Senior Vice President, General Counsel & Corporate Secretary
EP
Eric P. Kowack
Senior Vice President, Program Leadership & Alliance Management
MO
Mark Osterman, M.D., M.S.C.E.
Senior Vice President, Clinical Development (Autoimmune)
KR
Kirk Rosemark
Senior Vice President, Regulatory Affairs & Quality Assurance
JS
Jennifer Sandoz
Senior Vice President, Human Resources